China Betaferon Adherence, Coping and Nurse Support Study

Bayer110 enrolled

Overview

Non-adherence reduces treatment benefit and can bias the assessment of treatment efficacy thereby involving safety risks for the patient and influencing health cost-effectiveness. This observational study will concentrate upon the role of MS nurses in influencing adherence. This study will examine the influence of initial and subsequent periodic nurse interviews which aim to improve adherence to Betaferon® treatment.

Study Type

OBSERVATIONAL

Enrollment

110

Conditions

Multiple Sclerosis, Chronic Progressive

Interventions

Interferon beta-1b (Betaseron, BAY86-5046)DRUG

All patients will be prescribed with Betaseron and be instructed on treatment by their phisicians

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Relapsing-remitting multiple scelrosis (RRMS) and secondary progressive multiple sclerosis (SPMS) patients * Having Betaferon treatment, including patients who are * First time using; or * Re-staring; or * Switching from other diseases modifying drugs (DMDs) Exclusion Criteria: * Known or newly identified contraindication for administration of Betaferon according to Summary of Product Characteristic (SmPC).

Locations (1)

Unnamed facility

Many Locations, China

Outcomes

Primary Outcomes

Adherence to Betaferon treatment: proportion of patients adhering to Betaferon treatment

Time frame: at 6, 12, 18 and 24 months

Secondary Outcomes

Ways of Coping Questionnaire (WCQ)

Time frame: at 6, 12, 18 and 24 months

Hospital Anxiety and Depression Scale (HAD)

Time frame: at 6, 12, 18 and 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.